Lilly wins Alimta vitamin regimen patent case in UK
The pharma company had filed a lawsuit alleging that Teva Pharmaceutical subsidiary Actavis’ alternative salt forms had directly infringed the Alimta vitamin regimen patent in the UK, Spain,
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.